Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.

被引：0
|
作者：
Porcu, Pierluigi
Bagot, Martine
Ram-Wolff, Caroline
Kim, Youn H.
Huen, Auris
Dalle, Stephane
Poligone, Brian
Mehta-Shah, Neha
Modeste, Anne Benedicte Duval
Zinzani, Pier Luigi
Woei-A-Jin, Feng Jung Sherida Harriette
Eigentler, Thomas
Combalia, Andrea
Sokol, Lubomir
Battistella, Maxime
Gru, Alejandro
Teisserenc, Helene Moins
Viotti, Julien
Paiva, Christine
Chammard, Agnes Boyer
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[2] Univ Paris Cite, Hop St Louis, INSERM, U976, Paris, France
[3] Stanford Univ, Dept Dermatol, Multidisciplinary Cutaneous Lymphoma Program, Stanford, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX USA
[5] Hosp Civils Lyon, Dept Dermatol, Pierre Benite, France
[6] Rochester Skin Lymphoma Med Grp, PLLC, Fairport, NY USA
[7] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA
[8] CHU Rouen, Hop Charles Nicolle, Dept Dermatol, Rouen, France
[9] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy
[10] Univ Ziekenhuis Leuven, Dept Gen Med Oncol, Leuven, Belgium
[11] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergol, Berlin, Germany
[12] Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain
[13] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[14] Univ Paris Cite, Dept Pathol, Hop St Louis, INSERM U976, Paris, France
[15] Univ Virginia, Dept Pathol, Sch Med, Charlottesville, VA USA
[16] Univ Paris Cite, Hop St Louis, AP HP, Hematol Lab,INSERM 1160, Paris, France
[17] Innate Pharma, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7082
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
    Noriko Fukuhara
    Koji Kato
    Hideki Goto
    Tajima Takeshi
    Mayu Kawaguchi
    Kota Tokushige
    Koichi Akashi
    Takanori Teshima
    Hideo Harigae
    Stephen J. Schuster
    Catherine Thieblemont
    Martin Dreyling
    Nathan Fowler
    International Journal of Hematology, 2023, 117 : 251 - 259
  • [32] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
    Mehta-Shah, Neha
    Zinzani, Pier Luigi
    Jacobsen, Eric D.
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Gritti, Giuseppe
    Pinter-Brown, Lauren C.
    Izutsu, Koji
    Bentur, Ohad S.
    Sidransky, David
    Brammer, Jonathan E.
    Pro, Barbara
    Fox, Christopher P.
    Horwitz, Steven
    BLOOD, 2024, 144 : 3061 - 3062
  • [33] Update of the results of the phase 2 CREST trial, bortezomib in refractory or relapsed multiple myeloma
    Wemeau, Mathieu
    Leleu, Xavier
    HEMATOLOGIE, 2009, 15 (01): : 7 - 8
  • [34] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    S K Kumar
    B LaPlant
    V Roy
    C B Reeder
    M Q Lacy
    M A Gertz
    K Laumann
    M A Thompson
    T E Witzig
    F K Buadi
    C E Rivera
    J R Mikhael
    P L Bergsagel
    P Kapoor
    L Hwa
    R Fonseca
    A K Stewart
    A Chanan-Khan
    S V Rajkumar
    A Dispenzieri
    Blood Cancer Journal, 2015, 5 : e338 - e338
  • [35] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    Kumar, S. K.
    LaPlant, B.
    Roy, V.
    Reeder, C. B.
    Lacy, M. Q.
    Gertz, M. A.
    Laumann, K.
    Thompson, M. A.
    Witzig, T. E.
    Buadi, F. K.
    Rivera, C. E.
    Mikhael, J. R.
    Bergsagel, P. L.
    Kapoor, P.
    Hwa, L.
    Fonseca, R.
    Stewart, A. K.
    Chanan-Khan, A.
    Rajkumar, S. V.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e338 - e338
  • [36] Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study
    Foss, Francine
    Horwitz, Steven M.
    Coiffier, Bertrand
    Bartlett, Nancy
    Popplewell, Leslie
    Pro, Barbara
    Pinter-Brown, Lauren C.
    Shustov, Andrei
    Furman, Richard R.
    Haioun, Corinne
    Koutsoukos, Tony
    O'Connor, Owen A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04): : 238 - 243
  • [37] Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
    Di Bella, Nicholas
    Taetle, Raymond
    Kolibaba, Kathryn
    Boyd, Thomas
    Raju, Robert
    Barrera, David
    Cochran, Ernest W., Jr.
    Dien, Philip Y.
    Lyons, Roger
    Schlegel, Peter J.
    Vukelja, Svetislava J.
    Boston, Julie
    Boehm, Kristi A.
    Wang, Yunfei
    Asmar, Lina
    BLOOD, 2010, 115 (03) : 475 - 480
  • [38] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis
    Brammer, Jonathan E.
    Zinzani, Pier Luigi
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Jacobsen, Eric D.
    Gritti, Giuseppe
    Litwak, Debra
    Cohan, David
    Katz, Danica J.
    Mehta-Shah, Neha
    Pro, Barbara
    Horwitz, Steven M.
    BLOOD, 2021, 138
  • [39] Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Htut, Myo
    Gasparetto, Cristina
    Zonder, Jeffrey A.
    Martin, Thomas G., III
    Chen, Janice
    Brooks, Christopher
    McDonald, Peter
    Rupprecht, Nicole
    Wysowskyj, Halyna
    Chauhan, Dharminder
    Ray, Arghya
    Anderson, Kenneth C.
    Paba-Prada, Claudia E.
    BLOOD, 2019, 134
  • [40] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
12345